Skip to main content

Table 6 Comparison of individual AEs of >grade 3 for dabrafenib plus trametinib versus vemurafenib plus cobimetinib

From: Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

  Incidence (% patients) ITC results
COMBI-v coBRIM
AE type D + T (n = 350) V (n = 349) V (n = 239) V + T (n = 254) RR LCI UCI p value
Alopecia 0(0) 1(<1) 1(<1) 1(<1) 0.35 0.01 24.22 0.6295
Anemia 7(2.0) 4(1.2) 6(2.4) 4(1.6) 2.63 0.46 15.10 0.2787
Arthralgia 3(<1) 15(4.3) 12(4.9) 6(2.4) 0.40 0.08 1.91 0.2513
Asthenia 5(1.4) 4(1.2) 3(1.2) 5(2.0) 0.75 0.11 5.17 0.7711
Cutaneous squamous cell carcinoma 5(1.4) 62(17.8) 27(11.3) 6(2.4) 0.38 0.11 1.34 0.1337
Dermatitis acneiform 0(0) 4(1.2) 3(1.2) 6(2.4) 0.06 0.00 1.40 0.0792
Diarrhea 4(1.1) 2(<1) 2(<1) 16(6.5) 0.25 0.03 2.34 0.2242
Fatigue 4(1.1) 7(2.0) 7(2.9) 10(4.1) 0.40 0.09 1.88 0.2459
Hyperkeratosis 0(0) 2(<1) 6(2.4) 0(0) 2.60 0.04 169.50 0.6534
Hypertension 54(15.4) 33(9.5) 6(2.4) 11(4.5) 0.89 0.31 2.58 0.8353
Increased ALT 9(2.6) 15(4.3) 15(6.1) 28(11.3) 0.32 0.12 0.88 0.0280
Increased AST 5(1.4) 9(2.6) 5(2.0) 21(8.5) 0.13 0.03 0.56 0.0062
Increased blood ALP 7(2.0) 5(1.4) 4(1.6) 10(4.1) 0.56 0.11 2.82 0.4826
Increased blood CPK 6(1.7) 1(<1) 0(0) 28(11.3) 0.11 0.00 3.49 0.2076
Increased GGT 19(5.4) 17(4.9) 25(10.2) 32(13.0) 0.87 0.39 1.96 0.7436
Keratocanthoma 2(<1) 35(10.0) 20(8.1) 3(1.2) 0.38 0.06 2.44 0.3091
Maculopapular rash 2(<1) 13(3.7) 13(5.3) 17(6.9) 0.12 0.02 0.61 0.0105
Myalgia 0(0) 4(1.2) 6(2.4) 1(<1) 0.67 0.02 24.45 0.8258
Nausea 1(<1) 1(<1) 2(<1) 2(<1) 0.53 0.02 11.65 0.6871
Pain in extremity 4(1.1) 2(<1) 6(2.4) 3(1.2) 4.00 0.45 35.40 0.2121
Photosensitivity reaction 0(0) 1(<1) 0(0) 7(2.8) 0.02 0.00 1.62 0.0820
Pyrexia 16(4.6) 2(<1) 0(0) 4(1.6) 0.94 0.04 24.60 0.9712
Rash 3(<1) 30(8.6) 14(5.7) 13(5.3) 0.11 0.03 0.43 0.0017
SCC of skin 2(<1) 20(5.7) 31(12.6) 7(2.8) 0.44 0.08 2.32 0.3349
Vomiting 4(1.1) 3(<1) 3(1.3) 3(1.2) 0.94 0.09 9.60 0.9598
  1. AE adverse event, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, CPK creatine phosphokinase, GGT gamma-glutamyltransferase, LCI lower 95% CI, RR risk ratio, SCC squamous cell carcinoma, UCI upper 95% CI